But since then, someone did: The auction closed Monday afternoon, with a single bid at the $68,000 minimum Knome had set.

"We don't know who the [auction's] winner is," says Knome's Ari Kiirikki. "We know it's a male and we know he's from Europe." But as soon as the payment goes through, probably within days, the company will learn his identity, he adds, and the unknown man will join about 20 others who have had their genes sequenced by Knome.

Normally, the service-which includes an analysis by Knome's team of clinicians and geneticists so you can understand whether your genetic profile makes you susceptible to certain diseases, such as cancer or Alzheimer's-costs $99,500. It takes about three months to complete the process, says Kiirikki, Knome's vice president of sales and business development.

On a cold day in January, Dan Stoicescu, a millionaire living in Switzerland, became the second person in the world to buy the full sequence of his own genetic code. He is also among a relatively small group of individuals who could afford the $350,000 price tag.

Mr. Stoicescu is the first customer of Knome, a Cambridge-based company that has promised to parse his genetic blueprint by spring. A Chinese executive has signed on for the same service with Knome's partner, the Beijing Genomics Institute, the company said. Scientists have so far unraveled only a handful of complete human genomes, all financed by governments, foundations and corporations in the name of medical research. But as the cost of genome sequencing goes from stratospheric to merely very expensive, it is piquing the interest of a new clientele.

"I'd rather spend my money on my genome than a Bentley or an airplane," said Mr. Stoicescu, 56, a biotechnology entrepreneur who retired two years ago after selling his company. He says he will check discoveries about genetic disease risk against his genome sequence daily, "like a stock portfolio."

But while money may buy a full readout of the six billion chemical units in an individual's genome, biologists say the superrich will have to wait like everyone else to learn how the small variations in their sequence influence appearance, behavior, abilities, disease susceptibility and other traits.

*****

Biologists have mixed feelings about the emergence of the genome as a luxury item. Some worry that what they have dubbed "genomic elitism" could sour the public on genetic research that has long promised better, individualized health care for all. But others see the boutique genome as something like a $20 million tourist voyage to space -- a necessary rite of passage for technology that may soon be within the grasp of the rest of us.